Calixar
A world reference in the production of membrane proteins targets for drug and vaccine discovery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 39 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | 31 % | 24 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Eurofins CALIXAR, established in 2011, is a biotechnology company specializing in the production, solubilization, stabilization, and characterization of challenging recombinant active proteins. These proteins are crucial for various biological processes and serve as prime targets for drug development. Operating within the life sciences industry, Eurofins CALIXAR caters to research institutions and pharmaceutical companies engaged in drug discovery programs. The company generates revenue by providing custom protein solutions tailored to the specific needs of its clients, leveraging advanced technology to ensure high yield and optimal protein performance. In April 2023, Eurofins CALIXAR became part of the Eurofins Discovery group, further expanding its reach and capabilities. With a team of dedicated scientists, the company is committed to overcoming scientific challenges and advancing the understanding of proteins. Keywords: protein research, drug discovery, biotechnology, recombinant proteins, life sciences, pharmaceutical, research institutions, Eurofins Discovery, protein stabilization, scientific expertise.